Skip to main content
. 2021 May 9;24(1):502. doi: 10.3892/mmr.2021.12141

Figure 4.

Figure 4.

Validation of lentivirus silencing effect of ADAM33 in HASMCs. (A) Comparison of ADAM33 mRNA levels among HASMCs in groups of blank control (no treatment), LV-NC and ADAM33 silencing with LV-ADAM33-shRNA 1–3 with reverse transcription-quantitative PCR. (B) Comparison of ADAM33 protein levels among HASMCs in groups of blank control (no treatment), LV-NC and ADAM33 silencing with LV-ADAM33-shRNA with western blotting. (C) Semi-quantitative analysis for the ADAM33 protein levels among HASMCs in blank control, LV-NC and LV-ADAM33-shRNA groups. *P<0.05. ADAM33, a disintegrin and metalloproteinase-33; HASMCs, human aortic smooth muscle cells; LV, lentiviral vector; NC, negative control; shRNA, short-hairpin RNA.